Lantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline

Reuters2025-10-30

Lantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline

Lantern Pharma Inc. has published a new presentation highlighting its advancements in AI-driven oncology drug development. The company showcased its proprietary RADR® platform, which is designed to accelerate cancer drug discovery and development while reducing associated costs. According to the presentation, RADR® can predict and stratify patient responses for clinical trials with 88% accuracy, helping to compress early-stage drug development timelines by 70% and reduce costs by 80%. The presentation details Lantern's pipeline, which includes 10 disclosed drug programs and five clinical stage lead candidates, such as LP-300 for non-small cell lung cancer in never smokers (currently in Phase 2) and LP-284 for recurrent non-Hodgkin's lymphomas (advanced to Phase 1 in two years). The company has launched 10 new programs in two years and has active ongoing Phase 1 and Phase 2 clinical trials. RADR® is also being utilized to identify biomarkers and increase the probability of clinical trial success. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579121436?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 23:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579121436","market":"nz","top_or_hot":-1,"title":"Lantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LTRN\">Lantern Pharma Inc.</a> has published a new presentation highlighting its advancements in AI-driven oncology drug development. The company showcased its proprietary RADR® platform, which is designed to accelerate cancer drug discovery and development while reducing associated costs. According to the presentation, RADR® can predict and stratify patient responses for clinical trials with 88% accuracy, helping to compress early-stage drug development timelines by 70% and reduce costs by 80%. The presentation details Lantern's pipeline, which includes 10 disclosed drug programs and five clinical stage lead candidates, such as LP-300 for non-small cell lung cancer in never smokers (currently in Phase 2) and LP-284 for recurrent non-Hodgkin's lymphomas (advanced to Phase 1 in two years). The company has launched 10 new programs in two years and has active ongoing Phase 1 and Phase 2 clinical trials. RADR® is also being utilized to identify biomarkers and increase the probability of clinical trial success. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 23:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LTRN\">Lantern Pharma Inc.</a> has published a new presentation highlighting its advancements in AI-driven oncology drug development. The company showcased its proprietary RADR® platform, which is designed to accelerate cancer drug discovery and development while reducing associated costs. According to the presentation, RADR® can predict and stratify patient responses for clinical trials with 88% accuracy, helping to compress early-stage drug development timelines by 70% and reduce costs by 80%. The presentation details Lantern's pipeline, which includes 10 disclosed drug programs and five clinical stage lead candidates, such as LP-300 for non-small cell lung cancer in never smokers (currently in Phase 2) and LP-284 for recurrent non-Hodgkin's lymphomas (advanced to Phase 1 in two years). The company has launched 10 new programs in two years and has active ongoing Phase 1 and Phase 2 clinical trials. RADR® is also being utilized to identify biomarkers and increase the probability of clinical trial success. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL5X2b6Q:1","article_id":"2579121436","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579121436","pubTimestamp":1761838995,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lantern Pharma Inc. has published a new presentation highlighting its advancements in AI-driven oncology drug development. The company showcased its proprietary RADR platform, which is designed to accelerate cancer drug discovery and development while reducing associated costs. According to the presentation, RADR can predict and stratify patient responses for clinical trials with 88% accuracy, helping to compress early-stage drug development timelines by 70% and reduce costs by 80%. The presentation details Lantern's pipeline, which includes 10 disclosed drug programs and five clinical stage lead candidates, such as LP-300 for non-small cell lung cancer in never smokers  and LP-284 for recurrent non-Hodgkin's lymphomas . The company has launched 10 new programs in two years and has active ongoing Phase 1 and Phase 2 clinical trials. RADR is also being utilized to identify biomarkers and increase the probability of clinical trial success. You can access the full presentation through the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LTRN":"Lantern Pharma Inc."},"translate_title":"Lantern Pharma展示了人工智能驱动的癌症药物发现和临床管道进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LTRN":0.9},"content_text":"Lantern Pharma Showcases AI-Driven Advances in Cancer Drug Discovery and Clinical Pipeline\n    \n\nLantern Pharma Inc. has published a new presentation highlighting its advancements in AI-driven oncology drug development. The company showcased its proprietary RADR® platform, which is designed to accelerate cancer drug discovery and development while reducing associated costs. According to the presentation, RADR® can predict and stratify patient responses for clinical trials with 88% accuracy, helping to compress early-stage drug development timelines by 70% and reduce costs by 80%. The presentation details Lantern's pipeline, which includes 10 disclosed drug programs and five clinical stage lead candidates, such as LP-300 for non-small cell lung cancer in never smokers (currently in Phase 2) and LP-284 for recurrent non-Hodgkin's lymphomas (advanced to Phase 1 in two years). The company has launched 10 new programs in two years and has active ongoing Phase 1 and Phase 2 clinical trials. RADR® is also being utilized to identify biomarkers and increase the probability of clinical trial success. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lantern Pharma Inc. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579121436","isCrawlerRequest":true}